Effect Of Lactobacillus GG on Atopic March

Status Recruiting

Clinical Trial Summary

Food allergy (FA), defined as an adverse immune response to food allergens, is among the most frequent allergic disorders in childhood and it has recognized as a major paediatric health problem due to the severity of the reactions and the dramatic increase over the past decades. Cow's milk allergy (CMA) is the most frequent FA in children worldwide, and it has been demonstrated that it could be the first manifestation of the so-called "atopic march", characterized by the occurrence of other allergic disorders in the subsequent years after the onset of CMA. In a previous study, involving children with CMA over a period of 5 years, 40% developed asthma, 21% atopic eczema, and 43% allergic rhinitis. Similar results have been reported in a recent study on Finnish children Intestinal microflora appears to have a crucial role in the development of atopic disorders. Children with atopic diseases have different commensal bacterial groups in the gut compared to non-atopic children, and differences are also found between countries with high and low incidence of atopic diseases. There is currently great interest in manipulating the normal microbiota to accrue health benefits through an approach known as "probiotics." Probiotics are defined as "live microorganisms which when administered in adequate amounts confer a health benefit on the host". The conceptual basis of possible use of probiotics in the prevention and treatment of atopic disorders is well grounded. Lactobacillus GG (LGG) is the most studied probiotic in the prevention and treatment of atopic disorders. Wide and well-designed clinical studies have provided several evidences on the efficacy of LGG as preventive or therapeutic strategy in pediatric atopic disorders. More recently, in vitro studies have provided evidences on the potent immunoregulatory role and on the influence on intestinal microflora composition (toward a more beneficial composition in the prevention and treatment of atopic disorders) elicited by LGG. This view has been further reinforced by recent research showing that LGG is able to improve recovery of intestinal symptoms in infants with CMA-induced allergic colitis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01891916
Study type	Interventional
Source	Federico II University
Contact	Roberto Berni Canani, Phd
Email	ritanocerino@alice.it
Status	Recruiting
Phase	N/A
Start date	October 2008
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02738060` - The Effect of Baked Milk on Cow's Milk Allergy	Phase 2
Recruiting	`NCT02149134` - Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy	Phase 2
Completed	`NCT01622426` - Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy	N/A
Completed	`NCT01634490` - Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy	N/A
Completed	`NCT02466035` - Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)	N/A
Completed	`NCT02379598` - Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy	N/A
Completed	`NCT04330092` - Diagnosis of Cow's Milk Protein Allergy
Not yet recruiting	`NCT02081651` - Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy	Phase 3
Completed	`NCT03462030` - Baked Milk Oral Immunotherapy for Cow's Milk Allergy	Phase 2
Completed	`NCT02465905` - Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study	N/A
Suspended	`NCT05731206` - Hypoallergenicity of a Hydrolyzed Protein Infant Formula	N/A
Not yet recruiting	`NCT06456541` - Infant Formula in Infants and Children With Cow's Milk Allergy	N/A
Recruiting	`NCT02062476` - Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy	Phase 2
Completed	`NCT01589731` - Polymerized Beta-lactoglobulin Comparative Immunoreactivity	N/A
Terminated	`NCT02405923` - Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy	N/A
Terminated	`NCT04910373` - Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy	N/A
Recruiting	`NCT01968278` - Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients	N/A
Withdrawn	`NCT01470768` - Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas	N/A
Recruiting	`NCT05883384` - Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy
Completed	`NCT01901380` - Cow's Milk Allergy and Functional Gastrointestinal Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.